What Are the Fundamentals Of BBIO?

By Chris Stiles • Wednesday, October 11 10:29 • Permanent Link

Small-cap Health Care company BridgeBio Pharma has moved 0.0% so far today on a volume of 163,462, compared to its average of 3,025,534. In contrast, the S&P 500 index moved 0.0%.

BridgeBio Pharma trades -42.78% away from its average analyst target price of $46.4 per share. The 10 analysts following the stock have set target prices ranging from $33.0 to $60.0, and on average have given BridgeBio Pharma a rating of buy.

If you are considering an investment in BBIO, you'll want to know the following:

BridgeBio Pharma has moved 131.0% over the last year, and the S&P 500 logged a change of 23.0%
Based on its trailing earnings per share of -3.9, BridgeBio Pharma has a trailing 12 month Price to Earnings (P/E) ratio of -6.8 while the S&P 500 average is 15.97
BBIO has a forward P/E ratio of -9.4 based on its forward 12 month price to earnings (EPS) of $-2.83 per share
The company has a price to earnings growth (PEG) ratio of 0.13 — a number near or below 1 signifying that BridgeBio Pharma is fairly valued compared to its estimated growth potential
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.
Based in Palo Alto, the company has 392 full time employees and a market cap of $4.31 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.